The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BVXV | -61.6% | -99.73% | -69.42% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +219% |
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.19M | -32.5% |
| Gross Profit | -$0.67M | -690.6% |
| Gross Margin | -323.30% | 0.0% |
| Market Cap | $1.94M | 50.7% |
| Market Cap / Employee | $0.06M | 0.0% |
| Employees | 31 | 0.0% |
| Net Income | -$2.63M | -13.7% |
| EBITDA | -$1.78M | -0.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.99M | -69.2% |
| Accounts Receivable | $0.08M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.66M | -91.8% |
| Short Term Debt | $0.42M | 7.1% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Return On Assets | 24.20% | 0.0% |
| Return On Invested Capital | -4.56% | 40.6% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.09M | 29.1% |
| Operating Free Cash Flow | -$1.09M | 16.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 11.30 | 1.22 | 0.46 | 0.46 | - |
| Price to Book | -0.40 | 0.65 | 0.53 | 0.45 | -252.33% |
| Price to Sales | 8.23 | 6.45 | 4.33 | - | |
| Price to Tangible Book Value | -0.40 | 0.65 | 0.53 | 0.45 | -252.33% |
| Enterprise Value to EBITDA | -9.54 | -14.22 | -4.46 | -4.76 | -54.04% |
| Return on Equity | 99.4% | 138.4% | - | ||
| Total Debt | $20.63M | $20.82M | $1.23M | $2.09M | -89.85% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
